Literature DB >> 350251

Disposition of sodium valproate in epileptic patients.

E Perucca, G Gatti, G M Frigo, A Crema, S Calzetti, D Visintini.   

Abstract

1 Serum levels of valproic acid have been determined at fixed intervals after the administration of single oral and intravenous doses (800 mg) to six epileptic patients receiving chronic treatment with other antiepileptic drugs. 2 Serum levels declined monoexponentially shortly after the intravenous administration. Biological half-lives averaged 9.0 +/- 1.4 h (s.d.). Volumes of distribution were 0.175 +/- 0.025 l/kg. There was a statistically significant negative correlation between volumes of distribution and serum half-lives (P less than 0.005). 3 After oral doses serum levels rose rapidly to peak values within 0.5--2 h. Biological availability was 96 +/- 9%. 4 Comparison with a previous study performed according to the same protocol in healthy volunteers showed significantly increased volumes of distribution and rates of elimination in the patients. Total serum clearance was 85% higher in the patients as compared to the healthy subjects (P less than 0.001). Possible explanations for these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350251      PMCID: PMC1429371          DOI: 10.1111/j.1365-2125.1978.tb01663.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Pharmacokinetics and bioavailability of sodium valproate.

Authors:  U Klotz; K H Antonin
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

3.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

4.  Valproate may lower serum-phenytoin.

Authors:  P N Patsalos; P T Lascelles
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

5.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

6.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

7.  Determination of the anticonvulsant drug--dipropyl acetate (Epilim) in human plasma by gas chromatography.

Authors:  H U-Schulz; P A Toseland
Journal:  Ann Clin Biochem       Date:  1977-07       Impact factor: 2.057

  7 in total
  35 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.

Authors:  Anita Grover; Leslie Z Benet
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-04-16       Impact factor: 2.745

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  Effects on cimetidine bioavailability of metoclopramide and antacids given two hours apart.

Authors:  N Barzaghi; F Crema; G Mescoli; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Pharmacokinetics of valproic acid in the elderly.

Authors:  E Perucca; R Grimaldi; G Gatti; S Pirracchio; F Crema; G M Frigo
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

9.  Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers.

Authors:  N Barzaghi; G Gatti; R Manni; C A Galimberti; C Zucca; E Perucca; A Tartara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 10.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.